Director Lisa Glatch awarded 1,711 Xylem (NYSE: XYL) RSUs

Rhea-AI Filing Summary

Glatch Lisa reported acquisition or exercise transactions in this Form 4 filing.

Xylem Inc. director Lisa Glatch received a grant of 1,711 shares of common stock as a restricted stock unit award. The units were valued at $116.88 per share on the grant date and are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders. After this compensation-related award, she directly holds 6,874 Xylem shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Glatch Lisa

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,711	$116.88	$200K

Holdings After Transaction: Common Stock — 6,874 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 1,711 shares Grant value per share: $116.88 per share Total shares after grant: 6,874 shares +1 more

4 metrics

RSU grant size 1,711 shares Restricted stock unit award to director Lisa Glatch

Grant value per share $116.88 per share Transaction price per share for the RSU grant

Total shares after grant 6,874 shares Direct holdings following the transaction

Vesting timing Prior to 2027 Annual Meeting RSUs vest on trading day before 2027 shareholder meeting

Key Terms

restricted stock units, Xylem 2011 Omnibus Incentive Plan, Annual Meeting of Shareholders, non-derivative, +1 more

5 terms

restricted stock units financial

"Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Xylem 2011 Omnibus Incentive Plan financial

"pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016)"

Annual Meeting of Shareholders financial

"scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

non-derivative financial

"transaction_type": "non-derivative""

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glatch Lisa

(Last) (First) (Middle)

C/O XYLEM INC.

301 WATER STREET SE

(Street)

WASHINGTON DISTRICT OF COLUMBIA 20003

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xylem Inc. [ XYL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A		1,711(1)	A	$116.88	6,874	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders.

	/s/ Mike Nazario, by power of attorney for Lisa Glatch	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Xylem (XYL) director Lisa Glatch report?

Lisa Glatch reported an acquisition of Xylem shares through an award. She received 1,711 shares of Xylem common stock as a restricted stock unit grant, classified as a “grant, award, or other acquisition” rather than an open-market purchase or sale.

How many Xylem (XYL) shares were granted to Lisa Glatch and at what value?

Lisa Glatch was granted 1,711 Xylem common shares at $116.88 each. The filing shows a non-derivative acquisition of 1,711 shares with a transaction price per share of $116.88, reflecting the grant’s per-share valuation on the award date.

What type of equity award did Lisa Glatch receive from Xylem (XYL)?

The award consists of restricted stock units under a Xylem incentive plan. The footnote explains it is an RSU grant issued pursuant to the Xylem 2011 Omnibus Incentive Plan, as amended, which is part of the company’s equity-based compensation program.

When will Lisa Glatch’s Xylem (XYL) restricted stock units vest?

The restricted stock units are scheduled to vest in full before the 2027 meeting. They vest on the trading day immediately prior to Xylem’s 2027 Annual Meeting of Shareholders, according to the disclosure in the footnote.

How many Xylem (XYL) shares does Lisa Glatch own after this award?

Following the award, Lisa Glatch directly holds 6,874 Xylem shares. The Form 4 states that total shares following the transaction are 6,874, reflecting her direct ownership position after the restricted stock unit grant.

Was Lisa Glatch’s Xylem (XYL) award an open-market stock purchase?

No, the transaction was a compensatory grant, not an open-market buy. The filing classifies it under code “A” as a grant or award acquisition, and the footnote ties it to Xylem’s omnibus incentive plan, indicating equity compensation.